Search clinical trials for: AZD5985

Total 54 results

AstraZeneca

Recruiting

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

Ovarian Cancer | Lung Adenocarcinoma

Spain, China, United States, Australia, Taiwan, Canada, Israel, Japan, United Kingdom
AstraZeneca

Completed

Exploratory Study to Assess the Pharmacokinetics of AZD5985

Healthy

Germany
AstraZeneca

Terminated

AZD5985 Single Ascending Dose Study

Healthy

Sweden
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
AstraZeneca

Completed

AZD0585 Phase III Long-term Study in Japan

Hypertriglyceridemia

Japan
AstraZeneca

Completed

A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers (ADME)

Healthy
AstraZeneca

Completed

14729-D9831C00002- 1 Month Biopsy Study (Biopsy)

Chronic Obstructive Pulmonary Disease

United Kingdom, Germany, Netherlands
AstraZeneca

Completed

One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids (OLIVE)

Asthma

Poland, Argentina, Brazil, Costa Rica
AstraZeneca

Completed

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients (Sweapea)

Asthma Patients

United States, Mexico, Russian Federation, South Africa, Romania, Ukraine, Japan, Argentina, Slovakia, Brazil
AstraZeneca

Completed

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

Type 2 Diabetes

United States
AstraZeneca

Completed

Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours

Non-Small Cell Lung Cancer | Advanced Solid Tumours

United States, United Kingdom
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

Healthy Participants

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Idiopathic Pulmonary Fibrosis

United States
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
AstraZeneca

Completed

Single and Multiple Ascending Doses of AZD1981 in Japan (JSAD/JMAD)

Healthy

United Kingdom
AstraZeneca

Completed

A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives

Oral Contraceptives

Sweden
Insmed Incorporated

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
AstraZeneca

Completed

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

Healthy

Sweden
AstraZeneca
Parexel

Completed

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Healthy Volunteers

United States
AstraZeneca

Completed

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

Healthy | Postmenopausal | Surgically Sterile Women

Sweden
AstraZeneca

Recruiting

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA)

Hepatocellular Carcinoma

United States, Korea, Republic of
AstraZeneca

Completed

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

Pharmakokinetic

Sweden
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid (PET)

Alzheimer´s Disease

Sweden
Johns Hopkins University
AstraZeneca

Completed

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Chronic Idiopathic Urticaria

United States
AstraZeneca

Completed

Pharmacokinetics in Adolescents (PEAK)

Asthma

Sweden
AstraZeneca

Completed

To Investigate the Effects of AZD1981 on the QT Interval

Asthma

United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca
Parexel

Terminated

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Healthy Subjects

United Kingdom
AstraZeneca

Completed

Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study

Safety, Pharmacokinetics, Pharmacodynamics, Food Effect

United Kingdom
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca; University of... and other collaborators

Active, not recruiting

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca

Completed

A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin

Drug Interaction

Sweden
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
AstraZeneca

Completed

AZD1981 Midazolam CYP4503A Induction Study

Healthy Male Volunteer

Sweden
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
AstraZeneca

Active, not recruiting

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Romania, Moldova, Republic of
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaborators

Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)

Covid19

United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
Northwell Health
National Alliance for Research on Schizophrenia and Depression

Completed

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

Bipolar Depression | Unipolar Depression

United States
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
AstraZeneca

Completed

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Healthy Subjects

United Kingdom

3

Subscribe